Dermatology/Skin - Other

2

Review clinical trials related to Dermatology/Skin - Other. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

Cutaneous and Mucosal Manifestations of Neurofribromatosis Type 2 in Children Under 15

.Neurofibromatosis type 2 is an inherently autosomal dominant genetic disease, but cases of mosaicism or de novo mutation are not uncommon. the prevalence is estimated at 1 / 60,000. the clinical presentation is based on the appearance of tumors in the central and peripheral nervous system. The current average age of diagnosis is around 25 to 30 years depending on the studies. Currently, the diagnostic criteria are based on the ENT, neurological and opthalmological manifestations of the disease. Cutaneous manifestations have been described in these patients. Except now, mucocutaneous manifestations of the disease are not taken into account for depisatage or diagnosis. The purpose of this study would be to identify the different cutaneous and mucosal manifestations in a pediatric population under 15 years of age, and to analyze whether this might be of interest in early detection of the disease in association with other symptoms.

Participants needed: 1,000
Trial details
Age: 0-15Biological sex: AllType: ObservationalSponsor: Centre Hospitalier Universitaire de NiceUpdated: Jun 29, 2026Locations: 1
Eligibility criteria

age up to 15 years [+1]

refusal to participate in the study [+1]

Status: Recruiting

Application of the Belle.AI Dermatological Image Reference System for Patient Diagnosis in an Active Clinical Setting

The goal of this research study is to test a new, investigational tool that uses artificial intelligence (AI) to help primary care providers assess skin conditions. This tool is an AI-powered dermatology image reference app that works with a smartphone. For clarity, the AI makes no diagnoses; it provides reference images. Primary care providers then use their own medical judgement and training to make the diagnosis. The sponsor aims to compare the diagnoses made by primary care providers (such as doctors, nurse practitioners, and physician assistants) with the support of the AI tool compared to a panel of dermatologists, who are setting the gold standard. By doing so, the sponsor can determine the value of the AI tool for primary care providers and understand how it might be used alongside traditional clinical care. This AI capability complies with FDA regulatory guidelines and is not considered a medical device, similar to a Google image search, which returns similar looking images for reference purposes. For intervention, they healthcare providers use their own training and clinical judgement to make the diagnosis, and not the AI.

Participants needed: 263
Trial details
Biological sex: AllType: InterventionalSponsor: BelleTorus CorporationUpdated: Dec 9, 2024Locations: 1
Eligibility criteria

Patient must present to walk-in clinic with a primary dermatological complaint. [+2]

Patients who are unable to comply with study procedures due to physical or menta... [+1]